Skip to content

SS Innovations International

US · SSII #3689 by market cap
2.65 +0.02 +0.57%
Live - 5344 symbols - heartbeat 89s ago · 2026-10-09 20:02

Valuation each multiple against its own 5-year range

P/B ratio 10.26 Cheap vs history 2nd percentile
5-year average 45.40 · #109 of 125 in Medical Devices
P/E ratio -45.67 Expensive vs history 67th percentile
5-year average -63.87 · forward -45.67
P/S ratio 10.46 Cheap vs history 2nd percentile
5-year average 52.06 · forward 8.13 · #113 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
SS Innovations International (SSII) 529.00M -44.08 9.91 0.00%
Abbott Laboratories (ABT) 172.35B 32.23 3.37 2.45%
Medtronic (MDT) 113.18B 21.79 2.25 3.22%
Stryker Corp (SYK) 106.38B 28.74 4.43 1.25%
Boston Scientific (BSX) 61.93B 17.30 2.48 0.00%
Edwards Lifesciences (EW) 49.12B 49.54 4.63 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value3.60 Economic moatNone UncertaintyVery High

Trading 36.0% below Morningstar's fair value estimate.

Fair value

While SS Innovations International Inc may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 24% discount to our quantitative fair value estimate of $3.60 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's solid growth bolsters our fair value estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 122.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 237.4, for example, ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 20:02:38 · For reference only, not investment advice and not tailored to your situation.

SS Innovations International discussion 0 comments

Add a comment